Sarah A R Siegel1, Kevin L Winthrop2,3. 1. School of Public Health, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, GH 104, Portland, OR, 97239, USA. siegels@ohsu.edu. 2. School of Public Health, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, GH 104, Portland, OR, 97239, USA. 3. Division of Infectious Diseases, Oregon Health & Science University, Portland, OR, USA.
Abstract
PURPOSE OF REVIEW: To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease. RECENT FINDINGS: Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster. Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.
PURPOSE OF REVIEW: To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease. RECENT FINDINGS:Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster. Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Joel M Gelfand; Dafna D Gladman; Philip J Mease; Nana Smith; David J Margolis; Tamar Nijsten; Robert S Stern; Steven R Feldman; Tara Rolstad Journal: J Am Acad Dermatol Date: 2005-10 Impact factor: 11.527
Authors: Kim A Papp; Bruce Strober; Matthias Augustin; Steve Calabro; Anil Londhe; Marc Chevrier Journal: J Drugs Dermatol Date: 2012-10 Impact factor: 2.114
Authors: A Strangfeld; M Eveslage; M Schneider; H J Bergerhausen; T Klopsch; A Zink; J Listing Journal: Ann Rheum Dis Date: 2011-07-25 Impact factor: 19.103
Authors: K B Gordon; M Lebwohl; K A Papp; H Bachelez; J J Wu; R G Langley; A Blauvelt; B Kaplan; M Shah; Y Zhao; R Sinvhal; K Reich Journal: Br J Dermatol Date: 2021-11-24 Impact factor: 11.113
Authors: Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri Journal: Biomedicines Date: 2022-01-21